USPTO serial 88439354
ATAC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 1, 2022
- Examiner
- STURMAN, MELISSA M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ATAC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Heidelberg Pharma Research GmbH
Ladenburg, DE
Heidelberg Pharma Research GmbH
Ladenburg, DE
Heidelberg Pharma Research GmbH
Ladenburg, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Todd A. Sullivan
Todd A. Sullivan Hayes Soloway P.C.175 Canal StreetManchester, NH 03101United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, anti-cancer and immunosuppression preparations; pharmaceuticals, namely, anti-cancer and immunosuppression preparations; chemico-pharmaceutical preparations, namely, chemical preparations for medical purposes for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances, namely, pharmaceutical products for the treatment of cancer and immunosuppression; pharmaceutical preparations, namely, anti-cancer preparations for veterinary use; chemical preparations for pharmaceutical purposes, namely, chemical preparations for the treatment of cancer and immunosupression; pharmaceutical preparations for human use, namely, pharmaceutical preparations for human use in the treatment of cancer and immnunosupression; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for use in oncology; diagnostic preparations for medical purposes; diagnostic agents for pharmaceutical use; diagnostic agents for medical use; diagnostic preparations for veterinary purposes; clinical diagnostic reagents for medical use; diagnostic chemical reagents for medical use; anti-cancer drugs, namely, anti-cancer preparations; pharmaceutical compounds for treating cancer and immunosuppression; anti-cancer preparations; anti-cancer preparations of chemical origin; biopharmaceuticals, namely, anti-cancer preparations for the treatment of cancer and immunosuppression; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics; antibodies being pharmaceutical preparations for the treatment of cancer and immunosuppression; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression with agents including amatoxin | ACTIVE | — |
| 042 | Pharmaceutical research services; medical and pharmacological research services; pharmaceutical products development; development of pharmaceutical preparations and medicines; consultancy relating to pharmaceutical research and development; provision of medical research services; scientific research; medical research; biomedical research services; research relating to biotechnology; research on the subject of pharmaceuticals; consultancy relating to research in the field of pharmacogenetics; research and development in the pharmaceutical and biotechnology fields; research and development in the field of diagnostic preparations; research and development in the field of biotechnology; pharmaceutical research and development for the pharmaceutical industry; research and development services in the field of antibody technology; research and development services in the field of antibodies; scientific laboratory services relating to the production of monoclonal antibodies; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression | ACTIVE | — |
| 044 | Pharmaceutical advice; pharmaceutical consultation services; consultancy and information services relating to pharmaceutical products; all the aforesaid goods exclusively relating to the fields of oncology and/or immunosuppression | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Heidelberg Pharma Research GmbH
- Other trademarks owned by Heidelberg Pharma Research GmbH
- Other trademarks owned by Heidelberg Pharma Research GmbH
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ATAC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 4, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 4, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Feb 4, 2025 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Feb 4, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 4, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 4, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 4, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 1, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 1, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 16, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 16, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 27, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 8, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 6, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 5, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 5, 2022 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 13, 2022 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 13, 2022 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 13, 2022 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 29, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 29, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 15, 2021 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Oct 5, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Oct 5, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Oct 5, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Aug 25, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jan 5, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 5, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 5, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 5, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 5, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 7, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 7, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 7, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 4, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 4, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 25, 2020 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 23, 2020 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 23, 2020 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 23, 2020 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Nov 2, 2020 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 2, 2020 | ALIE | ASSIGNED TO LIE | — |
| Feb 26, 2020 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 26, 2020 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 26, 2020 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 11, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 10, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 10, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 9, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 9, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 9, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 8, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 5, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 24, 2019 | NWAP | NEW APPLICATION ENTERED | — |